UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~December~~April 3020, 2016

PRAXSYN CORPORATION

(Exact name of Registrant as specified in its charter)

Nevada	333-130446	20-3191557
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

61 Spectrum, Las Vegas, NV 89101 (Address of principal executive offices, including zip code) (949) 777-6112 (Registrant’s telephone number, including area code)

(Address of principal executive offices, including zip code)

(949) 777-6112

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

~~Item~~[ ] ~~1.01~~Soliciting ~~Entry~~material ~~into~~pursuant ato ~~Material~~Rule ~~Definitive~~14a-12 ~~Agreement~~under the Exchange Act (17 CFR 240.14a-12)

On[ ] ~~December 30, 2016, Praxsyn Corporation, a Nevada corporation (the “Company”), through its wholly~~Pre-~~owned~~commencement ~~subsidiary Nevada~~communications ~~Health~~pursuant ~~Rx,~~to ~~Inc.,~~Rule ~~a Nevada corporation~~ 14d-2(~~“NHRX”~~b), ~~entered~~under ~~into a Pharmacy Purchase and Sale Agreement, and amendments thereto (collectively~~ the ~~“Agreement”)~~Exchange ~~with~~Act ~~Duke Pharmacy, LLC, a Texas limited liability company~~ (~~“Duke”), to~~17 ~~purchase~~CFR ~~all of the assets, including but not limited to the pharmacy license, of Meds Direct Rx~~ 240.14d-2(~~the “Pharmacy”~~b).)

~~The~~[ ] ~~“Purchase~~Pre-commencement ~~Price”~~communications for the acquisition of the assets of the Pharmacy totaled One Hundred and Twenty Thousand Dollars ($120,000.00); Fifty Thousand Dollars ($50,000.00) which was paid on the closing date of February 28, 2017 to Duke, and the residual Seventy Thousand Dollars ($70,000.00) to be paid to Duke pursuant to aRule ~~promissory note, over a six month period, with an interest rate of six and a half percent~~ 13e-4(~~6.5%~~c) ~~per~~under ~~annum. However, no payments are due on~~ the ~~promissory~~Exchange ~~note~~Act ~~until~~(17 ~~May~~CFR ~~1, 2017~~240. ~~In connection with this transaction, the Company has received financing commitments through promissory notes and internal resources to fund the Purchase Price, transaction~~13e-~~related costs, and the ongoing business operations and capital needs of the Pharmacy~~4(c)).

~~NHRX is~~Item ~~a closed door retail pharmacy located at 61 Spectrum, Las Vegas, NV 89101~~5.02 ~~NHRX~~Departure ~~pharmacy~~of ~~license~~Directors ~~has~~or ~~been~~Certain ~~approved~~Officers; byElection ~~the Nevada Board~~ of ~~Pharmacy,~~Directors; ~~and~~Appointment ~~has passed its final inspection. The focus~~ of ~~NHRX~~Certain ~~shall~~Officers; beCompensatory toArrangements ~~service patients in the state~~ of ~~Nevada, California~~Certain ~~and Arizona~~Officers.

~~Item~~On 8April 20, 2017, Justin Cary resigned as Chief Financial Officer of Praxsyn Corporation, a Nevada corporation (the “Company”).01 Mr. ~~Other~~Greg ~~Events~~Sundem, who also serves as the Company’s Chief Executive Officer, President and Chairman of the Board, as reported in the Form 8-K as filed with the Securities and Exchange Commission on April 5, 2016, which is incorporated by this reference, was appointed by the unanimous consent of the Board of Directors as the Company’s Chief Financial Officer effective April 20, 2017.

~~Mesa~~On ~~Pharmacy~~May 15, 2017, Mr. Cary filed suit against the Company in the Superior Court of the State of California, County of Orange, for breach of contract and other employment related causes of action. Effective June 7, 2017, the Company and Mr. Cary entered into a settlement agreement, in which the Company shall pay Mr. Cary $16,225.50 (the “Settlement”). Other than the payment of the Settlement due to Mr. Cary on July 15, 2017, thereafter, the Company shall have no outstanding obligations due to Mr. Cary, including but not limited to the repayment of certain related party loans from Mr. Cary to the Company which have now been paid in full.

On ~~March~~the 3,same ~~2017,~~date atof adelivery ~~special meeting~~ of the ~~Board~~settlement ~~of Directors~~agreement, ~~the~~Mr. ~~majority~~Cary ofdelivered ~~the~~to ~~Board of Directors of~~ the Company, ~~voted in favor for Greg Sundem and Justin Cary, to work together on~~ a ~~plan~~resignation todated ~~take~~May ~~all actions necessary to discontinue the pharmacy operations of Mesa Pharmacy~~18, ~~Inc.~~2017, ~~d/b/a Mesa Pharmacy VII (“Mesa”). Although Mesa will continue to collect on its accounts receivables~~from ~~through~~his anposition ~~outside~~as ~~collection~~a ~~company,~~member ~~and~~of ~~will therefore continue to pay all outstanding debt from such collection efforts. By~~ the ~~end~~board of ~~April~~directors of ~~2017,~~the ~~Mesa will have filed all necessary paperwork to relinquish all pharmacy permits and licenses~~Company. Although Mesa will discontinue its pharmacy operations, Mesa will continue to maintain an office in California at 3183 Airway Ave, Suite 120, Costa Mesa, CA 92626, with four employees to process all mail and collections, and continue Mesa’s billing efforts on Mesa’s accounts receivable.

New Transfer Agent

As disclosed in the Company’s press release dated March 15 2017, VStock Transfer, LLC shall act as the Company’s official registrar of all stock records, shall be responsible for all certificate issuances, lost certificate replacements, certificate transfers, non-certificated book-entry transactions, restricted stock transfers, and digitized recordkeeping for shareholder communications and documentation.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	By:	/s/ Greg Sundem
		Greg Sundem, Chief Executive Officer
Dated: April 27, 2017

	By:	/s/ Greg Sundem
		Greg Sundem, Chief Executive Officer

Dated: June 28, 2017

Filing Compare · Praxsyn Corp